CHD1L

Across TCGA pan-cancer cohorts, CHD1L Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHD1L data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CHD1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHD1L expression acts as an unfavorable survival marker.

HNSC, STAD, and BRCA are the cancer types where CHD1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.169	0.751	<.001	42	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
BRCA	OS	Median	III,IV	0.514	0.906	.001	10	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHD1L–HNSC (OS)

Open the HNSC breakdown →